Professional
Added to YB: 2024-10-14
Pitch date: 2024-09-30
MRK [bullish]
Merck & Co., Inc.
+7.14%
current return
Author Info
No bio for this author
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$280.2B
Pitch Price
$108.16
Price Target
N/A
Dividend
3.00%
EV/EBITDA
10.81
P/E
31.73
EV/Sales
4.92
Sector
Pharmaceuticals
Category
value
Oakmark Equity and Income Fund New Position: Merck & Co., Inc.
MRK: Leading pharma w/ top oncology, vaccine & animal health. Keytruda dominates, but 2028 patent expiry fears create discount. Undervalued pipeline, strong cash flows cover stock price. Capable mgmt for reinvestment. Opportunity in life cycle mgmt & new products.
Read full article (1 min)